Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CRU | just throwing money away | 17/08/06 | 0 | 1.2K | |||
|
|||||||
CRU | moving nicely | 06/03/06 | 9 | 2.3K | |||
|
|||||||
CRU | going up | 19/07/04 | 3 | 1.0K | |||
|
|||||||
CRU | appears to have broken downtrend | 16/07/04 | 0 | 514 | |||
|
|||||||
CRU | lack of skilled workers | 06/07/04 | 1 | 837 | |||
|
|||||||
CRU | over 3 million in volume traded? | 21:34 | 0 | 481 | |||
|
|||||||
CRU | stock to watch by sanford today | 24/02/04 | 5 | 1.5K | |||
|
|||||||
CRU | price on the way up | 23/09/03 | 1 | 691 | |||
|
See All Discussions